Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
where to buy fat dildos? - LovToyLand.com
Popular Articles

Mysterious Ailments May Be The Result Of Undiagnosed Genetic Defects
One in every 3,000 babies is born with an inborn error of metabolism -- a genetic defect that interferes with their ability to process substances like carbohydrates, proteins and fats. Until recently, tests to detect many of these very rare, disabling, and sometimes fatal disorders like fatty acid oxidation disorders were rarely used. If the child died, the cause would be listed as unknown or Sudden Infant Death Syndrome (SIDS). If they survived, they would experience a range of symptoms and medical problems throughout their lives such as delays in development, seizures, difficulty with growth and autistic behavior.
diet pills
Microscopic "Beads" Could Help Create "Designer" Immune Cells That Ignore Transplanted Organs
The future of organ transplantation could include microscopic beads that create "designer" immune cells to help patients tolerate their new organ, Medical College of Georgia researchers say.
News of the day
Numbers Of Stroke Caused By Intracerebral Haemorrhage Have Increased By Around A Fifth In The Last Decade
Stokes caused by non-traumatic intracerebral haemorrhage (IH) are caused by a rupture of blood vessels in the brain. This is a major public health problem which accounts for 2 million (10-15%) of a total of 15 million strokes worldwide each year. The causes and the future treatment of this condition are discussed in a Seminar in this week"s edition of The Lancet, written by Dr Adnan I. Qureshi, (Zeenat Qureshi Stroke Research Center, University of Minnesota, USA); Dr A David Mendelow (University of Newcastle, UK); and Dr Daniel F Hanley (Johns Hopkins Medical Institutions, Baltimore, USA).
Sexual Health

Clinical Data, Inc. Expands FAMILION(R) Long QT Syndrome Test By Doubling The Number Of Genes

PGxHealth, a division of Clinical Data, Inc. (NASDAQ: CLDA), a biotechnology company developing targeted therapeutics and genetic and pharmacogenomic tests to detect diseases and predict drug safety, tolerability and efficacy, announced at the Heart Rhythm Society meeting that it will double the number of genes in its FAMILION Long QT Syndrome (LQTS) Test. By detecting genetic mutations in individuals and their families, the FAMILION LQTS Test can help guide treatment to prevent possible sudden cardiac death. This newly enhanced LQTS Test follows the 3-gene expansion of the FAMILION Hypertrophic Cardiomyopathy (HCM) Test released earlier this year and demonstrates the Company"s leadership in genetic testing for inherited cardiac disorders. "The addition of these five LQTS genes demonstrates our commitment to expand the scope of our tests as the clinical utility of new information is endorsed by the medical community," said Drew Fromkin, President and CEO of Clinical Data. "We are also pleased that the investments we have made in our laboratory operations, physician and patient support services and payor reimbursement function will enable us to offer this enhanced LQTS Test without increasing our price." Also at the Heart Rhythm meeting, PGxHealth scientists, together with academic collaborators, are presenting three scientific abstracts relating to inherited cardiac conditions. Presentations include: - Spectrum and Prevalence of Mutations for the First 2500 Consecutive Unrelated LQTS Patients Referred for FAMILION® Long QT Syndrome Genetic Testing. Abstract # PO03-4 - A Worldwide Compendium of Putative Brugada Syndrome Associated Mutations in the SCN5A-Encoded Cardiac Sodium Channel. Abstract # PO06-6 - Case-Control Genetic Comparison of the Cardiac Ryanodine Receptor in Catecholaminergic Polymorphic Ventricular Tachycardia. Abstract # PO02-160 "PGxHealth welcomes the opportunity to join academicians and healthcare providers from around the world again this year at the Heart Rhythm Society meeting, as we continue to disseminate vital information that will advance the understanding of heart disease and further inform treatment decisions," said Carol R. Reed, MD, Executive Vice President and Chief Medical Officer of Clinical Data. In related news, PGxHealth has filed a patent application with the Unites States Patent and Trademark Office pertaining to 336 new mutations in the Long QT genes. "This patent filing builds upon our existing intellectual property in LQTS testing and is consistent with our commitment to bring new and enhanced tests to physicians and their patients," added Fromkin. For More Information on the FAMILION family of tests, please contact PGxHealth Customer Service at 877-2-PGxHealth (877-274-9432) or visit http://www.pgxhealth.com. PGxHealth Clinical Data, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009